The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $23,476,855 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 150 grants at over 100 hospitals in 29 countries.




Institute of Cancer Research - $121,863

Amount
$121,863.00
Date
November 2019

Targeting Top3A-Amplified DIPG cells by Sirtuin inhibition.

Bambino Gesu Children's Hospital - $49,803

Amount
$49,803.00
Date
August 2019

Using imaging mass cytometry to identify next generation imaging biomarkers in PHGG and DIPG.

Telethon Kids Institute - $49,512

Amount
$49,512.00
Date
August 2019

Development of a new and effective therapy against Diffuse Intrinsic Pontine Glioma.

Oncoceutics ONC201 - Phase II - $83,333

Amount
$83,333.00
Date
May 2019

Expansion of the ONC201 Compassionate Use.

Funding of PBTCF 2019: PBTC-058 - $25,000

Amount
$25,000.00
Date
January 2019

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

Sydney Children’s Hospital - $175,089

Amount
$175,089.00
Date
November 2018

Polyamine Pathway Metabolism as a Novel Therapeutic Option for Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital - $540,742

Amount
$540,742.00
Date
November 2018

Expansion of the International DIPG Registry.

Bambino Gesú Children's Hospital - $99,382

Amount
$99,382.00
Date
November 2018

Investigating the Role of DIPG-Derived Exosomes in Tumor Growth and Invasion.

Ann and Robert H. Lurie Children's Hospital of Chicago - $35,000

Amount
$35,000.00
Date
November 2018

Credentialing an Improved DIPG Mouse Model.

Oncoceutics ONC201 - $83,333

Amount
$83,333.00
Date
October 2018

Expansion of the ONC201 Compassionate Use.

The Institute of Cancer Research - $100,000

Amount
$100,000.00
Date
October 2018

Short-pulse Ultrasound Delivery of Panobinostat for the Treatment of Diffuse Intrinsic Gliomas in Children

The Institute of Cancer Research - $106,647

Amount
$106,647.00
Date
October 2018

A Mouse Model of HIST1H3B/ACVR1 Mutant DIPG.

Johns Hopkins Children's Center - $50,000

Amount
$50,000.00
Date
July 2018

Using Zebrafish to Accelerate DIPG Drug Development.

Funding of PBTCF 2018: PBTC-058 - $16,800

Amount
$16,800.00
Date
January 2018

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

The Campbell Family Institute for Cancer Research - $100,000

Amount
$100,000.00
Date
October 2017

Defining the molecular mechanisms of DIPG development and progression to uncover novel therapeutic targets